Deutsche Bank reissued their hold rating on shares of Boston Scientific (NYSE: BSX) in a report released on Wednesday. Deutsche Bank currently has a $7.20 target price on the stock, up from their previous target price of $6.70.
“Accelerating growth seems more credible now, but it’s about execution. Boston Scientific held its last investor meeting in the fall of 2010. Then, as now, the company targeted accelerating top line growth. With several acquisitions and restructuring, we believe the company is in better financial shape today though there’s still a significant amount of risk on executing on the pipeline and with the core markets remaining stable. We left the analyst meeting more optimistic on the outlook and are raising our price target. However, given the stock’s recent move (up 32.5% YTD) and current price, we maintain our Hold rating.,” Deutsche Bank’s analyst wrote.
A number of other analysts have also recently weighed in on BSX. Analysts at Stifel Nicolaus raised their price target on shares of Boston Scientific from $8.00 to $9.00 in a research note to investors on Wednesday. They now have a buy rating on the stock. Separately, analysts at Barclays Capital reiterated an overweight rating on shares of Boston Scientific in a research note to investors on Tuesday. They now have a $8.00 price target on the stock. Finally, analysts at Citigroup reiterated a buy rating on shares of Boston Scientific in a research note to investors on Wednesday, January 30th. They now have a $8.20 price target on the stock, up previously from $7.30.
Eight research analysts have rated the stock with a buy rating, eighteen have given a hold rating, and one has issued a sell rating to the company’s stock. The stock presently has an average rating of – and an average target price of $7.65.
Shares of Boston Scientific remained flat at $7.53 during during mid-day trading trading on Wednesday. Boston Scientific has a 52 week low of $4.79 and a 52 week high of $7.73. The stock’s 50-day moving average is currently $6.. The company’s market cap is $10.209 billion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
